There is a growing evidence that OPMD wasn’t dumped but rather Axovant cancelled the whole contract because of growing financial pressure and limitations. The result is a blessing in disguise for Benitec and when the market wakes up to the fact that the science is still world class deserving of orphan designation, the share price will bounce hard. Presently some opportunists are peddling the story that the science is questionable and that disconnect will be exposed for what it is.
there are also rumours that OPMD will now be fast tracked towards trial readiness and as rare disease target should command a 500 million valuation.
BLT Price at posting:
7.3¢ Sentiment: Buy Disclosure: Held
